1-3 of 3
Xiaopan Yao, PhD, MS
Close
Sort by
Journal Articles

Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902

Selina Luger, MD, Xiaopan Yao, PhD, MS, Elisabeth Paietta, PhD, Rhett Ketterling, Witold Rybka, MD, Mark R. Litzow, MD, Jacob M. Rowe, Richard Larson, M.D., Martin S. Tallman, MD
Journal: Blood
Blood (2010) 116 (21): 3315.
https://doi.org/10.1182/blood.V116.21.3315.3315
Published: 2010
Journal Articles

Predictive Factors for All-Trans Retinoic Acid Related Differentiation Syndrome In Acute Promyelocytic Leukemia.

Houry Leblebjian, Pharm.D., Anne McDonnell, Pharm.D., BCOP, J. Andrew Skirvin, Pharm.D., BCOP, Martha Wadleigh, MD, Xiaopan Yao, PhD, MS, Donna Neuberg, ScD, Sylvia Bartel, R.Ph., M.H.P., Daniel J DeAngelo, MD, PhD, Richard M Stone, M.D.
Journal: Blood
Blood (2010) 116 (21): 1052.
https://doi.org/10.1182/blood.V116.21.1052.1052
Published: 2010
Journal Articles

Results of a Prospective Multicenter Phase II Study of Initial Treatment with Methotrexate In LGL Leukemia (ECOG Protocol E5998)

Thomas P. Loughran, Jr., MD, Xiaopan Yao, PhD, MS, John M. Bennett, MD, Mark R. Litzow, MD, Andrew M Evens, DO, MSc, Martin S. Tallman, MD
Journal: Blood
Blood (2010) 116 (21): 702.
https://doi.org/10.1182/blood.V116.21.702.702
Published: 2010